A head-to-head trial of Novo Nordisk’s next-generation obesity drug, CagriSema, has revealed disappointing results in comparison to rival Eli Lilly’s Mounjaro. The trial results have triggered a significant sell-off in
A head-to-head trial of Novo Nordisk’s next-generation obesity drug, CagriSema, has revealed disappointing results in comparison to rival Eli Lilly’s Mounjaro. The trial results have triggered a significant sell-off in






